A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
NCT04015024
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
SKLB1028 150mg bid
DRUG:
SKLB1028 200mg bid
DRUG:
SKLB1028 300mg qd
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.